论文部分内容阅读
目的：探讨地奥心血康（ＤＡＸＸＫ）治疗冠心病的作用机制。方法：５２例冠心病病人随机分为ＤＡＸＸＫ治疗组２６例（男性８例，女性１８例，年龄５６±ｓ８ａ）。采用ＤＡＸＸＫ２００ｍｇ，ｐｏ，ｔｉｄ，共４ｗｋ；对照组２６例（男性７例，女性１９例，年龄５７±８ａ）采用淀粉配制的片剂，２．２ｇ，ｐｏ，ｔｉｄ，共４ｗｋ。结果：ＤＡＸＸＫ组可显著降低血浆血栓烷Ｂ＿２（Ｐ＜０．０５），并提高红细胞—超氧化物歧化酶（ＳＯＤ）活性（Ｐ＜０．０１）；与对照组比较，Ｐ值均＜０．０１。结论：ＤＡＸＸＫ具有调节血栓烷Ａ＿２的降解产物血栓烷Ｂ＿２的水平，从而抑制小板的聚集及有使ＳＯＤ活性增加，有一定的抗脂质过氧化损伤作用，有利于心血管疾病的防治。
Objective: To explore the mechanism of action of DAXXK on coronary heart disease. Methods: Fifty-two patients with coronary heart disease were randomly divided into DAXXK treatment group (8 males and 18 females, age 56 ± s8a). DAXXK200mg, po, tid, a total of 4wk; control group of 26 patients (7 males and 19 females, age 57 ± 8a) tablets formulated with starch, 2.2g, po, tid, a total of 4wk. Results: Compared with the control group, the DAXXK group could significantly reduce the plasma thromboxane B 2 (P <0.05) and increase the activity of erythrocyte superoxide dismutase (SOD) (P <0.01) .01. CONCLUSION: DAXXK can regulate thromboxane B 2, a degradation product of thromboxane A 2, inhibits the aggregation of platelets and increases the activity of SOD, and has certain anti-lipid peroxidation injury effect, which is propitious to the prevention and treatment of cardiovascular diseases.